Bayforest Capital Ltd Buys 3,082 Shares of Johnson & Johnson $JNJ

Key Points

• Bayforest Capital Ltd increased its stake in Johnson & Johnson by 289.1%, acquiring 3,082 shares to hold a total of 4,148 shares valued at approximately $688,000.
• Johnson & Johnson reported a 2.77 EPS for the last quarter, exceeding expectations, with revenues of $23.74 billion, up 5.8% year-over-year.
• The company declared a quarterly dividend of $1.30 per share, representing a 2.9% yield, with an upcoming payment date of September 9th.

Bayforest Capital Ltd boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 289.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,148 shares of the company's stock after buying an additional 3,082 shares during the period. Bayforest Capital Ltd's holdings in Johnson & Johnson were worth $688,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Elios Financial Group Inc. increased its position in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after buying an additional 66 shares in the last quarter. Atlantic Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after purchasing an additional 67 shares in the last quarter. MBA Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc increased its holdings in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $178.30 on Tuesday. The company has a market capitalization of $429.40 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business's fifty day moving average is $169.09 and its 200 day moving average is $160.90. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Analyst Upgrades and Downgrades

A number of research firms have commented on JNJ. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Guggenheim reissued a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $176.29.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.